팔로우
Mohammed Yousuf Karim
Mohammed Yousuf Karim
Consultant Immunologist
nhs.net의 이메일 확인됨
제목
인용
인용
연도
C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites
JC Chambers, S Eda, P Bassett, Y Karim, SG Thompson, JR Gallimore, ...
Circulation 104 (2), 145-150, 2001
5682001
Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis
P Alba, L Bento, MJ Cuadrado, Y Karim, MF Tungekar, I Abbs, ...
Annals of the rheumatic diseases 62 (6), 556-560, 2003
2632003
Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents
MY Karim, P Alba, MJ Cuadrado, IC Abbs, DP D'Cruz, MA Khamashta, ...
Rheumatology 41 (8), 876-882, 2002
1952002
Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension
SR Sangle, DP D’Cruz, W Jan, MY Karim, MA Khamashta, IC Abbs, ...
Annals of the rheumatic diseases 62 (10), 999-1002, 2003
1312003
Presentation and prognosis of the shrinking lung syndrome in systemic lupus erythematosus
MY Karim, LC Miranda, CM Tench, PA Gordon, DP D'cruz, MA Khamashta, ...
Seminars in arthritis and rheumatism 31 (5), 289-298, 2002
1292002
Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients.
CN Pisoni, FJ Sanchez, Y Karim, MJ Cuadrado, DP D'Cruz, IC Abbs, ...
The Journal of rheumatology 32 (6), 1047-1052, 2005
1202005
Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome
P Alba, MY Karim, BJ Hunt
Lupus 12 (8), 633-635, 2003
1092003
Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens
MJ Cuadrado, Y Karim, G Sanna, E Smith, MA Khamashta, GRV Hughes
The American journal of medicine 118 (3), 246-250, 2005
902005
Whole-genome sequencing of a sporadic primary immunodeficiency cohort
SE Thaventhiran JED, Lango Allen H, Burren OS, Rae W, Greene D
Nature 583 (7814), 90-95, 2020
852020
Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers
S Sciascia, L Ceberio, C Garcia-Fernandez, D Roccatello, Y Karim, ...
Autoimmunity reviews 12 (2), 157-163, 2012
842012
Mycophenolate mofetil and systemic lupus erythematosus: an overview
CN Pisoni, Y Karim, MJ Cuadrado
Lupus 14 (3_suppl), 9-11, 2005
762005
The role of immune complexes in atherogenesis
DFP Burut, Y Karim, GAA Ferns
Angiology 61 (7), 679-689, 2010
692010
Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy
MY Karim, CN Pisoni, L Ferro, MF Tungekar, IC Abbs, DP D'Cruz, ...
Rheumatology 44 (10), 1317-1321, 2005
692005
Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil
CN Pisoni, G Obermoser, MJ Cuadrado, FJ Sanchez, Y Karim, NT Sepp, ...
Clinical and experimental rheumatology 23 (3), 393-396, 2005
692005
The role of cytokines as biomarkers in systemic lupus erythematosus and lupus nephritis
Z Adhya, S Borozdenkova, MY Karim
Nephrology Dialysis Transplantation 26 (10), 3273-3280, 2011
682011
Fresh-frozen plasma as a treatment for life-threatening ACE-inhibitor angioedema
MY Karim, A Masood
Journal of allergy and clinical immunology 109 (2), 370-371, 2002
682002
Normal complement C4 values do not exclude hereditary angioedema
Y Karim, H Griffiths, S Deacock
Journal of Clinical Pathology 57 (2), 213-214, 2004
652004
Update on immunotherapy for systemic lupus erythematosus—what's hot and what's not!
MY Karim, CN Pisoni, MA Khamashta
Rheumatology 48 (4), 332-341, 2009
622009
Beyond immunosuppression–challenges in the clinical management of lupus nephritis
S Masood, D Jayne, Y Karim
Lupus 18 (2), 106-115, 2009
492009
Update on therapy—thalidomide in the treatment of lupus
MY Karim, G Ruiz-Irastorza, MA Khamashta, GRV Hughes
Lupus 10 (3), 188-192, 2001
472001
현재 시스템이 작동되지 않습니다. 나중에 다시 시도해 주세요.
학술자료 1–20